These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39327962)

  • 41. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
    Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
    Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
    [No Abstract]   [Full Text] [Related]  

  • 42. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis.
    Jabbour E; Sasaki K; Haddad FG; Issa GC; Skinner J; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Garcia-Manero G; Takahashi K; Borthakur G; Pemmaraju N; Pierce S; Kantarjian H
    Am J Hematol; 2022 Nov; 97(11):1413-1418. PubMed ID: 36054032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.
    Ganesan P; Sagar TG; Dubashi B; Rajendranath R; Kannan K; Cyriac S; Nandennavar M
    Am J Hematol; 2011 Jun; 86(6):471-4. PubMed ID: 21538468
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic Factors, Response to Treatment, and Survival in Patients With Chronic Myeloid Leukemia in Blast Phase: A Single-Institution Survey.
    Pérez-Jacobo F; Tuna-Aguilar E; Demichelis-Gómez R; Crespo-Solís E; Valencia-Rocha U; Aguayo Á; López-Karpovitch X
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):778-84. PubMed ID: 26500135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Prognosis of clonal chromosomal abnormalities in Philadelphia negative metaphases cells in chronic myeloid leukemia with tyrosine kinase inhibitor therapy].
    Zhao HF; Zhang Y; Hu JY; Li Z; Zhou J; Yu FK; Zu YL; Zhou H; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2019 Mar; 40(3):209-214. PubMed ID: 30929388
    [No Abstract]   [Full Text] [Related]  

  • 46. [Long-term efficacy and prognostic factors of Beijing Children's Hospital-2009-lymphoblastic lymphoma in the treatment of T-lymphoblastic lymphoma in children and adolescents].
    Jin L; Yang J; Duan YL; Huang S; Zhang M; Zhou CJ; Zhang NN; Zhang YH
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(29):2759-2766. PubMed ID: 39075996
    [No Abstract]   [Full Text] [Related]  

  • 47. Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
    Bankar A; Lipton JH
    Leuk Lymphoma; 2022 Jan; 63(1):179-188. PubMed ID: 34493150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prognostic factors of pediatric patients with Ph-positive acute lymphoblastic leukemia].
    Xue YJ; Wu J; Zuo YX; Jia YP; Lu AD; Zhang LP
    Zhonghua Xue Ye Xue Za Zhi; 2018 Mar; 39(3):219-224. PubMed ID: 29562467
    [No Abstract]   [Full Text] [Related]  

  • 49. [Treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
    Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
    [No Abstract]   [Full Text] [Related]  

  • 50. [Analysis of clinical features and prognosis of patients with chronic myelogenous leukemia harboring additional chromosomal abnormalities in Ph-positive cells].
    Dong XY; Li YL; Wu CY; Shang BJ; Zhang L; Cheng W; Zhu ZM
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):660-665. PubMed ID: 34547872
    [No Abstract]   [Full Text] [Related]  

  • 51. High
    Vigneri P; Stagno F; Stella S; Cupri A; Forte S; Massimino M; Antolino A; Siragusa S; Mannina D; Impera SS; Musolino C; Malato A; Mineo G; Tomaselli C; Murgano P; Musso M; Morabito F; Molica S; Martino B; Manzella L; Müller MC; Hochhaus A; Raimondo FD
    Clin Cancer Res; 2017 Dec; 23(23):7189-7198. PubMed ID: 28928163
    [No Abstract]   [Full Text] [Related]  

  • 52. Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents.
    Millot F; Guilhot J; Suttorp M; Güneş AM; Sedlacek P; De Bont E; Li CK; Kalwak K; Lausen B; Culic S; Dworzak M; Kaiserova E; De Moerloose B; Roula F; Biondi A; Baruchel A
    Haematologica; 2017 Oct; 102(10):1704-1708. PubMed ID: 28838993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
    Dulucq S; Etienne G; Morisset S; Klein E; Chollet C; Robbesyn F; Turcq B; Tigaud I; Hayette S; Nicolini FE; Mahon FX
    Ann Hematol; 2019 May; 98(5):1159-1168. PubMed ID: 30798348
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Comparison of nilotinib
    Yu L; Qin YZ; Lai YY; Shi HX; Huang XJ; Hou Y; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):996-1002. PubMed ID: 32023729
    [No Abstract]   [Full Text] [Related]  

  • 56. [Report of Chinese Children's Cancer Group acute lymphoblastic leukemia 2015 multicenter study].
    Chinese Children′s Cancer Group Acute Lymphoblastic Leukemia 2015 Study Group
    Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1002-1010. PubMed ID: 36207846
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Factors influencing severe cytopenia in chronic phase chronic myeloid leukemia patients receiving initial second generation tyrosine kinase inhibitors and its impact on treatment responses and outcomes].
    Li ZY; Qin YZ; Lai YY; Shi HX; Hou Y; Zhang XS; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):295-301. PubMed ID: 37356998
    [No Abstract]   [Full Text] [Related]  

  • 59. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.
    Fava C; Rege-Cambrin G; Dogliotti I; Gottardi E; Berchialla P; Di Gioacchino B; Crasto F; Lorenzatti R; Volpengo A; Daraio F; Fantino C; Saglio G
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S96-S100. PubMed ID: 27131622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis.
    Castagnetti F; Testoni N; Luatti S; Marzocchi G; Mancini M; Kerim S; Giugliano E; Albano F; Cuneo A; Abruzzese E; Martino B; Palandri F; Amabile M; Iacobucci I; Alimena G; Pane F; Martinelli G; Saglio G; Baccarani M; Rosti G
    J Clin Oncol; 2010 Jun; 28(16):2748-54. PubMed ID: 20439635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.